CoChat
Sign Up
Cited by 622Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, Anne C., Hopkins, Paul N., Toth, Peter P., Ballantyne, Christie M., Rader, Daniel J., Robinson, Jennifer G., Daniels, Stephen R., Gidding, Samuel S., de Ferranti, Sarah D., Ito, Matthew K., McGowan, Mary P., Moriarty, Patrick M., Cromwell, William C., Ross, Joyce L., Ziajka, Paul E.·2011·Journal of clinical lipidology
DOI 10.1016/j.jacl.2011.03.001
Open this paper in CoChat — free account

Abstract

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2011.03.001

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 163 references

Cited by

Sorted by citations

Items 601–622 of 622

Related

See all

Metadata

Authors
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., McGowan, M. P., Moriarty, P. M., Cromwell, W. C., Ross, J. L., & Ziajka, P. E.
Affiliations
  • Washington University in St. Louis (US)
  • University of Utah (US)
  • CGH Medical Center (US)
  • Baylor College of Medicine (US)
  • University of Pennsylvania (US)
  • University of Iowa (US)
  • Children's Hospital Colorado (US)
  • Alfred I. duPont Hospital for Children (US)
  • Oregon State University (US)
  • Concord Hospital (US)
  • University of Kansas Medical Center (US)
  • Wake Forest University (US)
  • University of Pennsylvania Health System (US)
Corresponding author
Goldberg, Anne C.
ORCID
Venue
Journal of clinical lipidology
Publisher
Elsevier BV
Published
2011-05
Volume
5
Issue
3
Pages
133-140
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
DOI
10.1016/j.jacl.2011.03.001
OpenAlex
W2943032204
Cited by
622
References
163
Citations by year
2026: 13 · 2025: 16 · 2024: 15 · 2023: 22 · 2022: 23 · 2021: 55 · 2020: 53 · 2019: 39 · 2018: 63 · 2017: 47 · 2016: 76 · 2015: 58 · 2014: 56 · 2013: 47 · 2012: 28
FWCI
45.77
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of clinical lipidology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
familial hypercholesterolemia, screening, diagnosis, lipid-lowering therapy, LDL cholesterol lowering, coronary heart disease risk, pediatric patients, underdiagnosis, primary care, genetic lipid disorders
MeSH terms
Proprotein Convertase 9, Adult, Anticholesteremic Agents, Apolipoproteins B, Child, Coronary Disease, Genetic Testing, Homozygote, Humans, Hyperlipoproteinemia Type II, Mutation, Serine Endopeptidases, Practice Guidelines as Topic, LDL-Receptor Related Proteins, Proprotein Convertases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review